1. The future of urate-lowering strategies for gout

3. Program Overview

4. Disease Burden of Gout

5. Risk Factors for Gout

6. Risk Factors for Gout (cont)

7. Patients With CKD Have an Increased Risk for Gout

8. CV Events Are a Leading Cause of Death in Patients With Gout

9. Measuring sUA Levels

10. EULAR Recommendations for sUA Levels

11. EULAR Recommendations for ULT

12. EULAR Recommendations for Treating Flares

13. Risk for Flares With ULT

14. How Can sUA Levels Be Improved?

15. Why Are sUA Targets Not Being Met?

16. Why Are sUA Targets Not Being Met? (cont)

17. Novel ULTs for Gout - Lesinurad

18. Renal Function Does Not Reduce the Effectiveness of Lesinurad

19. Lesinurad as Monotherapy

20. Lesinurad in Combination With Febuxostat

21. Effect of ULT on Tophi and Flares

22. Novel Therapies in Development - Arhalofenate

23. Arhalofenate - Phase 2 Trial Data

24. Using ULT in Clinical Practice

25. Wider Benefits From Treating Gout

26. Summary

27. Summary (cont)

28. Abbreviations

29. Abbreviations (cont)

30. References

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)